Krascendo 1 strengthens the case for choosing a next-generation inhibitor before resistance to the drug class develops.
Roche’s investigational divarasib improved survival compared with sotorasib or adagrasib in previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). The result provides direct evidence for choosing between targeted therapies, while leaving a separate question unresolved: whether divarasib can help after an existing KRAS inhibitor stops working.
Key Takeaways
- Median overall survival was 17.7 months versus 12.0 months, favoring divarasib over the combined sotorasib-or-adagrasib control arm.
- The advance is clinical performance within an established mechanism: divarasib traps KRAS G12C in its inactive state.
- Krascendo 1 does not establish a treatment for acquired KRAS-inhibitor resistance. Previously treated patients were eligible, but prior KRAS/RAS inhibitor exposure was excluded.
Data Snapshot
| Measure | Divarasib | Sotorasib or adagrasib |
|---|---|---|
| Randomized patients | 167 | 171 |
| Median overall survival (OS) | 17.7 months | 12.0 months |
| Median progression-free survival (PFS) | 9.8 months | 5.7 months |
| Confirmed objective response rate | 58% | 32% |
| Treatment-related adverse events leading to discontinuation | 4.8% | 11.7% |
| Serious treatment-related adverse events | 7.8% | 15.2% |
The hazard ratio was 0.56 for death (95% confidence interval: 0.41–0.78) and 0.58 for progression or death (0.44–0.76). Response rates used the response-evaluable population of 328 patients. The control results pool two drugs and should not be read as separate estimates against each. (Roche’s detailed results)
What Krascendo 1 Revealed
Roche presented the detailed findings at the European Society for Medical Oncology (ESMO) Congress on October 25, 2026.
Krascendo 1 randomized 338 adults with previously treated advanced or metastatic disease. The primary endpoint was progression-free survival assessed by blinded independent central review; overall survival was a key secondary endpoint.
Success on both endpoints had already been announced in July. The October disclosure adds the effect sizes needed to assess the clinical importance of that success. (July topline announcement)
The overall-survival finding comes from the first interim analysis. The difference between the two medians is 5.7 months, but that is a population-level comparison—not an additional lifespan every patient can expect. (OncLive’s Krascendo 1 results coverage)
Why the Head-to-Head Comparison Matters
Comparisons between separate trials can be distorted by differences in patients, follow-up and assessment methods. Krascendo 1 offers stronger evidence by randomizing patients within one study against approved drugs targeting the same mutation.
The eligibility criteria define where that evidence applies. Patients who had received a KRAS G12C inhibitor or a pan-KRAS/RAS inhibitor were excluded. (Fierce Biotech’s ESMO coverage)
My interpretation is that this trial primarily informs which KRAS G12C inhibitor to choose after prior systemic treatment. It does not establish a sequence in which sotorasib or adagrasib is followed by divarasib after resistance develops.
How Divarasib Keeps KRAS Switched Off
KRAS cycles between an active state bound to guanosine triphosphate (GTP) and an inactive state bound to guanosine diphosphate (GDP).
Divarasib binds covalently to the mutant cysteine in the switch-II pocket of GDP-bound KRAS G12C, stabilizing the inactive state. Structural research confirms this binding arrangement. (Divarasib–KRAS G12C structural study)
GTP hydrolysis returns KRAS to its GDP-bound state. Divarasib captures that inactive form and prevents the nucleotide exchange required for reactivation. KRAS G12C retains cycling activity, which makes this trapping strategy possible. (KRAS G12C trapping mechanism)
Reduced KRAS activation weakens downstream RAF–MEK–ERK growth signaling. The drug does not directly inhibit those three kinases or work by blocking GTP hydrolysis.
Safety and the Remaining Questions
Fewer treatment-related discontinuations support the clinical relevance of the efficacy result: an effective therapy also needs to be tolerable enough to continue.
That does not remove the need for monitoring. Reported treatment-related toxicities included diarrhea, nausea, vomiting and hepatotoxicity. Divarasib remained investigational in the October announcement, so these findings represent clinical evidence supporting regulatory review, rather than an approval. (Genentech’s safety and development update)
Longer follow-up will help assess the durability of the survival advantage. Activity after resistance to another KRAS inhibitor requires evidence from an appropriately studied population.
BP View
Divarasib’s immediate opportunity is to influence the first choice of KRAS G12C inhibitor after prior systemic therapy.
The combination of a randomized active comparator, an overall-survival benefit and fewer treatment-related discontinuations makes this a persuasive result. It gives physicians and regulators more to evaluate than response rates from an early, single-arm study.
The distinction between better initial inhibition and overcoming acquired resistance should remain central. Both matter to patients, but they are different clinical problems. Krascendo 1 advances the first; the second remains open.
For the industry, the result reinforces the value of testing an improved molecule against established competitors. A familiar target can still yield meaningful progress when the improvement survives a direct clinical comparison.
Does this result change how you view next-generation KRAS inhibitors? If you have questions or a different perspective, leave a comment below.
Related Post
For another approach to RAS targeting, read my previous analysis of Rasonque (daraxonrasib) and its broader active-state strategy.
Revolution Medicines Wins FDA Approval for Rasonque in Metastatic Pancreatic Cancer
About BP
Biopharma Perspective examines drug-development milestones through clinical evidence, biological mechanisms and their implications for the industry.
Leave a Reply